: New Data On Safety And Efficacy In Type 2 Diabetes Patients With Renal Impairment)
Data presented at the American Diabetes Association (ADA) 73rd Scientific Sessions® provides insights for use of Trajenta® (linagliptin) in adults with Type 2 Diabetes (T2D) with moderate to severe renal impairment
Read more
Trajenta® (Linagliptin): New Data On Safety And Efficacy In Type 2 Diabetes Patients With Renal Impairment